Table 3.

Chemotherapy and risk of ONJ.

	Crude		Adjusted†
Cancer and Chemotherapy	Odds Ratio	95% C.I	Odds Ratio	95% C.I
Bevacizumab	5.00	0.70 – 35.50	2.83	0.02 – 463.35
Bone Marrow Transplant	0.63	0.14 – 2.84	0.69	0.10 – 4.62
Busulfan	1.49	0.28 – 7.93	0.50	0.05 – 5.12
Capecitabine	19.56*	2.24 – 171.02	1.08	0.07 – 16.42
Carboplatin	2.76	0.29 – 26.53	4.66	0.00 – 5.08e+08
Cyclophosphomide	0.77	0.30 – 1.98	0.79	0.17 – 3.67
Docetaxel	5.79	0.91 – 36.92	0.70	0.00 – 10801.39
Doxorubicin	0.90	0.30 – 2.74	0.54	0.09 – 3.34
Etoposide	2.24	0.11 – 44.88	0.48	0.00 – 43839.61
Gemcitabine	6.22*	1.50 – 25.68	2.87	0.17 – 48.50
Interferon	0.80	0.08 – 8.04	0.02	0.00 – 97805.93
Melphalan	0.77	0.23 – 2.63	0.56	0.11 – 2.81
Methotrexate	0.42	0.05 – 3.90	0.62	0.02 – 23.71
Paclitaxel	6.34*	1.47 – 27.34	23.54	0.30 – 1867.83
Statin	1.66	0.70 – 3.96	2.26	0.60 – 8.52
Steroid High Dose	0.35	0.10 – 1.22	0.56	0.08 – 3.81
Steroid Low Dose	3.28*	1.44 – 7.51	0.72	0.18 – 2.84
Tamoxifen	1.73	0.38 – 7.74	0.88	0.05 – 16.59
Thalidomide	2.40	0.68 – 8.54	1.97	0.39 – 10.04
Trastuzumab	2.50	0.23 – 27.57	67.95	0.35 – 13140.06
Vinorelbine	23.40*	2.75 – 199.31	109.70	0.38 – 31679.47

^*p<0.05

^†adjusted for metastasis, zoledronate, obesity, and smoking